1,298 material Form 8-K filings that 1,057 companies we cover made with the SEC in April 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On April 14, 2026, California Resources entered into a ninth amendment to its credit agreement with Citibank, N.A. as administrative agent. The amendment changes the pricing grid to reduce the company's borrowing costs under the facility, along with other technical changes.
Amendment dated effective April 14, 2026, to the Amended and Restated Credit Agreement dated April 26, 2023
Purpose includes amending the pricing grid to reduce borrowing costs under the facility
Citibank, N.A. serves as administrative and collateral agent; full text filed as Exhibit 10.1 with some portions omitted
TransDigm Inc., a subsidiary of TransDigm Group, completed $1.5 billion of new debt on April 17, 2026: $500 million of 6.125% senior subordinated notes due 2034 and $1.0 billion of tranche N term loans due 2033. The company plans to use the proceeds, with cash on hand, to fund the purchase price of the expected Stellant Systems acquisition and about $800 million of share repurchases made in March 2026.
New notes: $500 million of 6.125% senior subordinated notes maturing July 31, 2034, issued at 100.375% of principal
New term loans: $1.0 billion at Term SOFR plus 2.50%, maturing February 13, 2033, fully drawn April 17, 2026
Proceeds to fund Stellant Systems acquisition and about $800 million of common share repurchases completed in March 2026
On April 15, 2026, Bloomia Holdings' borrowers made a $4,900,000 initial payment toward a discounted prepayment of their bridge loan under a Second Amendment. Any unpaid portion accrues 12% interest and must be paid by May 27, 2026, or the bridge loan balance will be reduced based on the unpaid share. The company also borrowed $1,000,000 from Gary Kohler under an unsecured note at a fixed 11.5% rate, which it used to fund the payment.
Initial payment of $4,900,000 made April 15, 2026, against a $7,330,000 discounted prepayment amount; the minimum required was $4,800,000.
Unpaid discounted prepayment balance accrues 12% interest from April 16, 2026, with full payment due by May 27, 2026.
If the balance is not paid by May 27, 2026, the $15,097,053 bridge loan balance is reduced in proportion to the unpaid amount.
Unsecured $1,000,000 promissory note from Gary Kohler dated April 1, 2026, bears 11.5% interest and matures March 31, 2029.
Danaher signed a new $5.0 billion 364-day revolving credit facility with Bank of America as administrative agent, expiring April 15, 2027. The company says it will use the facility for liquidity support for its U.S. dollar commercial paper program and general corporate purposes.
Facility size is $5.0 billion, entered April 16, 2026, and expires April 15, 2027
Term SOFR loans carry a margin of 58.5 to 108.5 basis points, depending on Danaher's long-term debt rating
Danaher must maintain a Consolidated Leverage Ratio of 0.65 to 1.00 or less and pays a 4.0 basis point facility fee on commitments
Certain changes of control would constitute an event of default
Trevi Therapeutics agreed to sell 11.6 million new common shares at $13.00 each, for about $150 million before fees, with the Company estimating net proceeds of about $141.1 million. The Company said it had about $171.8 million in cash and securities as of March 31, 2026, and that this cash plus the offering proceeds will fund operations through 2029, while the sale also adds new shares outstanding for existing holders.
Offering of 11.6 million shares at $13.00 per share, with underwriters at $12.22 per share; closing expected on or about April 20, 2026.
Estimated net proceeds of about $141.1 million, or about $162.4 million if the 1,740,000-share underwriter option is exercised in full.
Cash, cash equivalents and marketable securities of about $171.8 million as of March 31, 2026, preliminary and unreviewed by the auditor.
Company expects cash to fund operations through 2029; first Phase 3 trial topline results expected in the first half of 2028.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.